Completed PHASE4 INTERVENTIONAL 1-arm NCT04182191

Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam

Influence of Cytochrome P450 (CYP2C9) Genotype on Clinical Efficacy of Tenoxicam After Lower Third Molars Surgeries

Sponsor: University of Sao Paulo

Interventions Tenoxicam

Updated 4 times since 2020 Last updated: Nov 27, 2019 Started: Mar 1, 2018 Primary completion: Jul 1, 2019 Completion: Nov 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04182191, this PHASE4 trial focuses on Molar, Third and Pain and remains completed. Sponsored by University of Sao Paulo, it has been updated 4 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2020 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Mar 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Sao Paulo

Data source: University of Sao Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bauru, Brazil